On September 11, 2026 Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, reported that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) (ENA) Symposium 2026 on Molecular Targets and Cancer Therapeutics taking place November 18 to 20, 2026 in Barcelona, Spain. The conference plans to release further details for abstracts on November 4, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presenter Abstract Title Presentation Details
Vikas Prasad, Washington University School of Medicine Cohort level safety and efficacy results for [212Pb]VMT-α-NET in advanced somatostatin receptor subtype 2 (SSTR2+)-expressing neuroendocrine tumors (NETs): Cohorts 1–3 Abstract Number: 334
Session Type: Poster session
Session Title: New drugs
Session Date: November 20, 2026
Session Time: 9:00am – 3:00pm CET / 3:00am – 9:00 am EST
About [²¹²Pb]VMT-α-NET

Perspective designed [212Pb]VMT-α-NET to target somatostatin receptor subtype 2 (SSTR2), and to deliver the alpha-emitting radioisotope lead-212, or ²¹²Pb, to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation and dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive tumors who have not received prior radiopharmaceutical therapies (RPT).

Interim clinical data from the study, with a data cut-off date of April 17, 2026, were presented at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in May 2026. These data included efficacy results for half of the patients in Cohort 2 and both patients in Cohort 1. Initial efficacy data for the remaining patients in Cohort 2 and patients in Cohorts 3 and 4 are pending. The Company plans to submit additional data for presentation at future medical conferences in 2026 and 2027.

(Press release, Perspective Therapeutics, SEP 11, 2026, View Source [SID1234670763])

On September 11, 2026 Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, reported that the Company will participate in the H.C. Wainwright 28th Annual Global Investment Conference, taking place in New York City September 14-16, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On Wednesday, September 16, 2026, at 10:30 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, Charles Morris, MBChB, MRCP. Chief Medical Officer, Peggy Scherle, Ph.D., Chief Scientific Officer, and Bryant Lim, Chief Financial Officer will participate in a fireside chat.

A live webcast of the fireside chat can be accessed on the Company’s website under Events and Presentations. The recording will be archived and available on the Company’s website for 90 days.

(Press release, Prelude Therapeutics, SEP 11, 2026, https://www.globenewswire.com/news-release/2026/09/11/3360242/0/en/prelude-therapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference.html [SID1234670762])

On September 11, 2026 ABL Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (the "Company"), a company specialized in molecular diagnostics solutions, healthcare software and services supporting clinical research, reported that it has filed, on Friday, September 11, 2026, a bid to acquire the business operations and assets of IntegraGen, a company specializing in genomic analysis of nucleic acids, particularly in oncology and rare genetic diseases, currently subject to judicial reorganization proceedings before the Commercial Court of Évry.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This initiative is consistent with ABL Diagnostics’ growth strategy and its ongoing evaluation of external growth opportunities complementary to its current portfolio.

The proposed acquisition, filed pursuant to Article L.642-1 of the French Commercial Code, remains subject to the decision of the Commercial Court of Évry. At this stage, there can be no assurance that ABL Diagnostics will be selected as the successful bidder.

The Company will keep the market informed of any material developments regarding this matter in accordance with applicable regulatory requirements.

Regulatory Information

This press release contains inside information within the meaning of Article 7 of Regulation (EU) No. 596/2014 on market abuse ("MAR"). Its disclosure is made in accordance with Article 17 of MAR. Forward-looking statements contained herein are inherently subject to risks and uncertainties, including those related to the outcome of judicial proceedings and the approval of third parties.

(Press release, Integragen, SEP 11, 2026, View Source [SID1234670761])

On September 11, 2026 Owkin, the agentic AI company pioneering the first automated AI scientist to revolutionize drug discovery and development, reported an agreement with Servier, an independent international pharmaceutical group governed by a foundation, to license K Pro, Owkin’s AI Scientist, together with multimodal patient data to advance the company’s oncology research.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the agreement, Owkin will make multimodal patient data from its MOSAIC network accessible for analysis to Servier’s research teams, within K Pro. This agreement is the next chapter in Owkin and Servier’s collaboration, their previous work together being in patient subgroup identification, also in oncology.

K Pro is Owkin’s AI scientist. It brings multimodal patient data and specialized biological agentic AI to drive smarter and faster decision-making to each step of the pharmaceutical value chain. K Pro utilizes specialized biological tools, leveraging a decade of knowledge gained through pharmaceutical partnerships and state-of-the-art AI research. K Pro delivers molecule optimization, target discovery, biomarker identification, subgroup optimization and clinical trial design. K Pro is trained and validated on real-world patient data and through Owkin’s wet lab.

"Our AI scientist is changing the way biopharma works," said Thomas Clozel, CEO and co-founder of Owkin. "By pairing K Pro with Owkin’s multimodal patient data, Servier’s scientists can investigate the biology of hard-to-treat cancers and reach answers that manual analysis alone cannot deliver."

"At Servier, we are constantly looking for new ways to deepen our understanding of disease biology and to bring better treatments to patients with hard-to-treat cancers. Access to high-quality patient data and AI-driven analysis in one place, through K Pro, helps our teams generate and test hypotheses with greater speed and confidence. We look forward to applying these capabilities across our oncology research," said Claude Bertrand, Executive Vice President, Research & Development, Servier.

(Press release, Owkin, SEP 11, 2026, View Source [SID1234670760])

On September 11, 2026 Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing therapeutics based on its proprietary INTASYL siRNA gene-silencing technology designed to eliminate cancer, reported that members of its management team will be available for one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, at the Lotte New York Palace Hotel in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Robert Bitterman, President and Chief Executive Officer, and Lisa Carson, Chief Financial Officer, will be available for meetings with investors throughout the conference. At the conference, management will discuss the Company’s clinical lead candidate PH-762, strategic priorities, and upcoming initiatives designed to support continued execution and long-term value creation.

Phio Pharmaceuticals’ Presentation
A webcast of Phio Pharmaceuticals’ presentation is available through the following link: Journey

Conference Details
Event: H.C. Wainwright 28th Annual Global Investment Conference
Dates: September 14-16, 2026
Location: Lotte New York Palace Hotel, New York, NY

(Press release, Phio Pharmaceuticals, SEP 11, 2026, https://phiopharma.com/phio-pharmaceuticals-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference/ [SID1234670758])